Advertisement

Progress in Anti-Cancer Chemotherapy

  • Gabriel N. Hortobagyi
  • David Khayat
Conference proceedings

Part of the Progress in Anti-Cancer Chemotherapy book series (ANTI-CANCER, volume 3)

Table of contents

  1. Front Matter
    Pages i-3
  2. Conceptual Advances in Cancer Research

  3. Ethic and Fundamental Research in Cancer

    1. Front Matter
      Pages 55-55
    2. C. J. D. Isaacs, B. N. Peshkin
      Pages 57-80
    3. I. J. Fidler, D. R. Bielenberg
      Pages 81-96
  4. Lung Cancer

    1. Front Matter
      Pages 57-57
    2. F. A. Greco, J. D. Hainsworth
      Pages 99-108
    3. G. Motta
      Pages 109-130
    4. A. F. Soriano, P. A. Bunn Jr.
      Pages 131-174
  5. Urological Tumors

    1. Front Matter
      Pages 175-175
    2. L. H. Einhorn
      Pages 177-188
  6. Melanoma

    1. Front Matter
      Pages 199-199
  7. Infectious Agents and Cancers

    1. Front Matter
      Pages 231-231
    2. B. E. Griffin
      Pages 246-261
    3. J.-Q. Huang, R. H. Hunt
      Pages 262-275
  8. Advances in solid tumors

    1. Front Matter
      Pages 277-277
    2. R. E. Pollock
      Pages 279-293

About these proceedings

Introduction

This is the third volume of our series Progress in Anti-Cancer Chemo­ therapy. Following the strategy of the first two volumes, it covers selected aspects of progress in this fast moving field of Oncology, with contribu­ tions from some of the world's best known leaders in both basic and clin­ ical research. This year we focused on seven areas: Three prominent Clinical investigators reviewed conceptual advances in cancer research. Dr Buzdar presented a history and overview of the protection of human subjects who participate in clinical research, and the mechanisms developed to assure the ethical conduct of research on human beings. Frei reviewed an exciting and rapidly moving area of che­ motherapy of solid tumors, including a cogent discussion of the issues related to dose-intensification. Fisher summarized conceptual advances in our therapeutic approach to breast cancer and the paradigm shifts that lead us to our current management strategies. From this summary he pro­ jected breast cancer research into the future, a daunting task under any circumstance. Fundamental research in cancer biology has been responsible for our improved understanding of the development and progession of malignant disease. Such understanding will lead to improved diagnosis, therapy, and eventually, prevention. Isaacs reviews the area of hereditary breast cancer, a topic undergoing rapid transformation and with mUltiple impli­ cations in the daily practice of medicine. Fidler, an international expert in metastasis research reviews the potential utility of angiogenesis inhib­ itors in research and the therapeutic ramifications.

Keywords

angiogenesis breast cancer cancer cancer therapy carcinogenesis cell chemotherapy interferon liver lung cancer melanoma pancreatic cancer prostate cancer screening surgery

Editors and affiliations

  • Gabriel N. Hortobagyi
    • 1
  • David Khayat
    • 2
  1. 1.MD Anderson Cencer Center, Cepartment of Breast Medical OncologyUniversity of TexasHoustonUSA
  2. 2.Pitié-Salpétrière HospitalSOMPSParis Cedex 13France

Bibliographic information

Industry Sectors
Pharma
Health & Hospitals
Biotechnology